MX2018002038A - Formulaciones clinicas. - Google Patents

Formulaciones clinicas.

Info

Publication number
MX2018002038A
MX2018002038A MX2018002038A MX2018002038A MX2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A
Authority
MX
Mexico
Prior art keywords
clinical
cells
preparations
tissue
cell
Prior art date
Application number
MX2018002038A
Other languages
English (en)
Spanish (es)
Inventor
Gay Roger
RATLIFF Judson
E Southwick Romma
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of MX2018002038A publication Critical patent/MX2018002038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
MX2018002038A 2015-08-18 2016-08-18 Formulaciones clinicas. MX2018002038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Publications (1)

Publication Number Publication Date
MX2018002038A true MX2018002038A (es) 2018-07-06

Family

ID=56843032

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002038A MX2018002038A (es) 2015-08-18 2016-08-18 Formulaciones clinicas.
MX2022010363A MX2022010363A (es) 2015-08-18 2018-02-16 Formulaciones clinicas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010363A MX2022010363A (es) 2015-08-18 2018-02-16 Formulaciones clinicas.

Country Status (15)

Country Link
US (3) US11013808B2 (cg-RX-API-DMAC7.html)
EP (1) EP3334415A1 (cg-RX-API-DMAC7.html)
JP (3) JP7043392B2 (cg-RX-API-DMAC7.html)
KR (3) KR102651291B1 (cg-RX-API-DMAC7.html)
CN (2) CN108697641A (cg-RX-API-DMAC7.html)
AU (2) AU2016308818B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003031B1 (cg-RX-API-DMAC7.html)
EA (2) EA202190722A1 (cg-RX-API-DMAC7.html)
HK (1) HK1256839A1 (cg-RX-API-DMAC7.html)
IL (3) IL299326A (cg-RX-API-DMAC7.html)
MX (2) MX2018002038A (cg-RX-API-DMAC7.html)
PH (1) PH12018500371B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201913250SA (cg-RX-API-DMAC7.html)
TW (3) TWI833293B (cg-RX-API-DMAC7.html)
WO (1) WO2017031312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
IL273405B2 (en) 2014-12-30 2024-01-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
SG10201907918VA (en) 2015-03-23 2019-10-30 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
KR102651291B1 (ko) 2015-08-18 2024-03-26 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
CN109414457A (zh) * 2016-06-30 2019-03-01 希里欧斯株式会社 移植用介质
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
BR112020013238A2 (pt) * 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
KR20220049618A (ko) 2019-08-28 2022-04-21 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병 치료 조성물 및 방법
JP2022547832A (ja) 2019-08-28 2022-11-16 アステラス インスティテュート フォー リジェネラティブ メディシン 血管疾患の処置方法
KR20220106965A (ko) 2019-10-30 2022-08-01 아스텔라스 인스티튜트 포 리제너러티브 메디슨 망막 색소 상피 세포의 생성 방법
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
CN117915772A (zh) * 2021-07-15 2024-04-19 二氧化硅医疗产品公司 用于核酸和生物样品的防腐剂组合物及其使用方法
CN118871141A (zh) * 2022-03-16 2024-10-29 住友制药株式会社 移植用介质
CA3259999A1 (en) 2022-07-18 2024-01-25 Astellas Institute For Regenerative Medicine METHODS OF TREATING A BRAIN INJURY
WO2024044134A1 (en) 2022-08-23 2024-02-29 Astellas Institute For Regenerative Medicine Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders
JPWO2024172043A1 (cg-RX-API-DMAC7.html) * 2023-02-14 2024-08-22
WO2025122978A1 (en) * 2023-12-06 2025-06-12 Bluerock Therapeutics Lp Cell cryopreservation and delivery vehicle and methods of using the same
WO2025158056A1 (fr) * 2024-01-26 2025-07-31 Treefrog Therapeutics Composition biocompatible adaptee pour l'administration de therapies cellulaires et son utilisation notamment la maladie de parkinson
FR3158633A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible comprenant des éléments cellulaires hétérogènes
FR3158635A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible particulière comprenant des éléments cellulaires hétérogènes utile pour l’administration de thérapies cellulaires
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
DE69227179D1 (de) * 1992-03-27 1998-11-05 Chen Chung Ho Mittel für Gewebe zur Erhaltung der Lebensfähigkeit und biologische Funktionen in der Chirurgie und Lagerung
CN1102851C (zh) 1993-06-04 2003-03-12 生物时间公司 类血浆溶液
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
WO1999009953A1 (fr) 1997-08-22 1999-03-04 Shimizu Pharmaceutical Co., Ltd. Preparation contenant du glucose
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
KR100550023B1 (ko) 2000-01-11 2006-02-09 가부시키가이샤 오프테꾸스 눈 수술용 관류액 제제
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
EP4248752A3 (en) 2004-01-23 2024-01-03 President And Fellows Of Harvard College Improved modalities for the treatment of degenerative diseases of the retina
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
EP2377925A1 (en) 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
KR101849329B1 (ko) 2007-10-12 2018-04-16 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Ｒｐｅ 세포의 개선된 생산 방법 및 ｒｐｅ 세포의 조성물
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
KR20180127528A (ko) 2008-05-06 2018-11-28 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포 및 비-생착성 혈관 세포
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
KR20180086301A (ko) 2009-12-04 2018-07-30 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
AU2010326027A1 (en) 2009-12-04 2012-06-21 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
HUE054517T2 (hu) 2010-07-23 2021-09-28 Astellas Inst For Regenerative Medicine Eljárások sejtek ritka alpopulációinak detektálására és nagymértékben tisztított sejtkészítmények
IL320536A (en) 2011-11-14 2025-06-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human RPE cells and their use
CA2857545A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
SI2788472T1 (sl) 2011-12-06 2019-04-30 Astellas Institute For Regenerative Medicine Način usmerjene diferencijacije, produciranja endotelijskih celic roženice
CN103783031B (zh) * 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
AU2013201546B2 (en) * 2012-12-18 2014-10-23 Gambro Lundia Ab Dialysis composition
ES2896354T3 (es) 2012-12-21 2022-02-24 Astellas Inst For Regenerative Medicine Métodos para la producción de plaquetas a partir de células madre pluripotentes
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
CN118995611A (zh) 2013-03-15 2024-11-22 安斯泰来再生医药协会 由多能干细胞产生的光感受器和光感受器祖细胞
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
SG11201701709YA (en) 2014-09-05 2017-04-27 Astellas Inst For Regenerative Medicine Retinal ganglion cells and progenitors thereof
SG10201907918VA (en) 2015-03-23 2019-10-30 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
KR102651291B1 (ko) * 2015-08-18 2024-03-26 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
KR20220049618A (ko) 2019-08-28 2022-04-21 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병 치료 조성물 및 방법
JP2022547832A (ja) 2019-08-28 2022-11-16 アステラス インスティテュート フォー リジェネラティブ メディシン 血管疾患の処置方法
KR20220106965A (ko) 2019-10-30 2022-08-01 아스텔라스 인스티튜트 포 리제너러티브 메디슨 망막 색소 상피 세포의 생성 방법
BR112023021993A2 (pt) 2021-05-03 2024-02-20 Astellas Inst For Regenerative Medicine Métodos de geração de células endoteliais da córnea madura

Also Published As

Publication number Publication date
WO2017031312A1 (en) 2017-02-23
NZ740608A (en) 2023-09-29
AU2022206757B2 (en) 2024-09-05
TWI833293B (zh) 2024-02-21
CN119112939A (zh) 2024-12-13
IL291163B2 (en) 2023-05-01
KR102411018B1 (ko) 2022-06-20
TWI772270B (zh) 2022-08-01
JP2018523682A (ja) 2018-08-23
CA2995977A1 (en) 2017-02-23
EP3334415A1 (en) 2018-06-20
KR102651291B1 (ko) 2024-03-26
TW201717912A (zh) 2017-06-01
IL299326A (en) 2023-02-01
US20240350639A1 (en) 2024-10-24
US11957754B2 (en) 2024-04-16
IL257551B (en) 2022-04-01
BR112018003031B1 (pt) 2023-12-26
KR20220090583A (ko) 2022-06-29
US12419958B2 (en) 2025-09-23
US20210275673A1 (en) 2021-09-09
KR20180048722A (ko) 2018-05-10
EA037915B1 (ru) 2021-06-07
JP7043392B2 (ja) 2022-03-29
BR112018003031A2 (pt) 2018-09-18
JP2022040140A (ja) 2022-03-10
AU2016308818B2 (en) 2022-04-21
KR20230058544A (ko) 2023-05-03
PH12018500371A1 (en) 2018-08-29
EA202190722A1 (ru) 2021-10-29
EA201890516A1 (ru) 2018-09-28
CN108697641A (zh) 2018-10-23
IL291163A (en) 2022-05-01
SG10201913250SA (en) 2020-03-30
US20190358330A9 (en) 2019-11-28
IL291163B1 (en) 2023-01-01
TW202245816A (zh) 2022-12-01
TW202417023A (zh) 2024-05-01
JP2024074803A (ja) 2024-05-31
HK1256839A1 (zh) 2019-10-04
PH12018500371B1 (en) 2023-01-20
JP7449915B2 (ja) 2024-03-14
AU2022206757A1 (en) 2022-08-18
IL257551A (en) 2018-04-30
MX2022010363A (es) 2022-09-21
AU2016308818A1 (en) 2018-04-05
US20190030168A1 (en) 2019-01-31
US11013808B2 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
MX2018002038A (es) Formulaciones clinicas.
CL2023000294A1 (es) Expresión selectiva de un transgene de tejidos
MX2018007519A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
SA521421559B1 (ar) أجهزة قابلة للزرع للعلاج بالخلايا وطرق ذات الصلة
MX2017003136A (es) Implante medico/quirurgico.
CU24495B1 (es) Compuestos que expanden las células hematopoyéticas y método ex vivo para expandir las células hematopoyéticas
MX2018005274A (es) Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
MX390753B (es) Metodos para reprogramar celulas y usos de los mismos.
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
MX383334B (es) Celulas discogenicas aisladas, metodos de uso, y metodos de preparacion de las mismas a partir de tejido de mamifero.
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
AR099557A1 (es) Fgf-18 en trasplantes de injertos y procedimientos de ingeniería de tejido
MX2020004811A (es) Métodos y composiciones de reconstrucción no mieloablativa de médula ósea.
CR20150310A (es) Solución para preservar conductos vasculares
MX377300B (es) Terapia con células madre en patologías endometriales.
MX2018004243A (es) Regimenes de dosificacion.
MX386236B (es) Metodos para aumentar el progreso genetico en una linea o raza de cerdo con celulas de esperma seleccionadas por sexo
AR077309A1 (es) Celulas derivadas del tejido cardiaco
CR20170466A (es) Material de implante compuesto